Multiple Myeloma Drug Sequence

For patients with newly diagnosed multiple myeloma (NDMM) eligible for autologous stem cell transplant (ASCT), the standard quadruplet regimen is **Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (D-VRd)**. Based on the retrieved prescribing information for **Darzalex Faspro (daratumumab/hyaluronidase-fihj)** [2], the sequence of administration is critical for safety and efficacy. The recommended sequence is: 1. **Daratumumab (subcutaneous)** 2. **Bortezomib (subcutaneous or intravenous)** 3. **Lenalidomide (oral)** 4. **Dexamethasone (oral or intravenous)** This sequence is derived from the clinical trial protocol for D-VRd, which specifies that daratumumab is administered first, followed by bortezomib, and then the oral agents (lenalidomide and dexamethasone) [2]. ### Detailed Dosing Schedule (D-VRd for Transplant-Eligible NDMM) The dosing schedule is divided into an Induction phase and a Post-ASCT Consolidation phase, using a 4-week cycle [2]. | Phase | Weeks | Daratumumab SC (Darzalex Faspro) | Bortezomib SC/IV | Lenalidomide PO | Dexamethasone PO/IV | | :--- | :--- | :--- | :--- | :--- | :--- | | **Induction** | Weeks 1–8 | **Weekly** (8 total doses) | Twice weekly (Days 1, 4, 8, 11) | 25 mg daily (Days 1–14) | 20 mg (Days 1, 2, 4, 5, 8, 9, 11, 12) | | **Induction** | Weeks 9–16 | **Every 2 weeks** (4 total doses) | Twice weekly (Days 1, 4, 8, 11) | 25 mg daily (Days 1–14) | 20 mg (Days 1, 2, 4, 5, 8, 9, 11, 12) | | **ASCT** | — | **Pause** during high-dose chemotherapy and transplant | — | — | — | | **Consolidation** | Post-ASCT (Weeks 1–8) | **Every 2 weeks** (4 total doses) | Twice weekly (Days 1, 4, 8, 11) | 15 mg daily (Days 1–14) | 20 mg (Days 1, 2, 4, 5, 8, 9, 11, 12) | **Key Administration Notes [2][3]:** - **Daratumumab**: Administer the subcutaneous injection first. The first dose of the every-2-week schedule in induction begins at Week 9. Post-ASCT, the first dose of the every-2-week schedule begins at Week 1 upon re-initiation of treatment. - **Bortezomib**: Administered after daratumumab. - **Lenalidomide & Dexamethasone**: These are oral medications taken after the injectable agents. - **Dose Adjustments**: The lenalidomide dose is reduced from 25 mg to 15 mg during the consolidation phase post-ASCT [2]. ### Guideline Context The **NCCN Guidelines (Version 5.2026)** [1] support the use of D-VRd as a preferred induction regimen for transplant-eligible NDMM, followed by daratumumab + lenalidomide (DR) maintenance. The sequence described above is the standard protocol from the PERSEUS trial, which demonstrated high rates of sustained MRD negativity with this approach [1]. --- ### Further Diagnostic Suggestions (Reference Only) To enable a more accurate assessment, if available, please consider providing: * **Patient's ASCT eligibility status**: The dosing schedule differs significantly between transplant-eligible (D-VRd) and transplant-ineligible (D-Rd or D-VMP) patients. * **Specific formulation of daratumumab**: The sequence and dosing are specific to the subcutaneous formulation (Darzalex Faspro). The IV formulation (Darzalex) has a different schedule. --- **Disclaimer**: This information is synthesized from retrieved prescribing information and clinical guidelines. Always verify the specific sequence and dosing against the latest official drug labels and institutional protocols before administration. Clinical judgment should be applied based on individual patient factors.